Drug absorption, distribution, metabolism and excretion considerations in critically ill adults

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 9, 2013, Pages 1067-1084

  Roberts, Derek J ^a   Hall, Richard I ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Critical care; Critical illness; Drug absorption; Drug clearance; Drug distribution; Intensive care unit; Pharmacokinetics; Wounds and injuries

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ATAZANAVIR; BETA LACTAM ANTIBIOTIC; BLOOD CLOTTING FACTOR 10A INHIBITOR; CEFEPIME; CEFPIROME; CEFTAZIDIME; CIMETIDINE; CLOPIDOGREL; DIGOXIN; DIPYRIDAMOLE; ENOXACIN; ENOXAPARIN; FLUCONAZOLE; GATIFLOXACIN; HYPERTENSIVE FACTOR; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; MINOCYCLINE; NIFEDIPINE; OMEPRAZOLE; PHENYTOIN; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNINDEXED DRUG; VANCOMYCIN; WARFARIN;

ABDOMINAL INJURY; AREA UNDER THE CURVE; ARTIFICIAL VENTILATION; BLOOD BRAIN BARRIER; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; EXTRACORPOREAL OXYGENATION; FLUID SHIFT; FOOD DRUG INTERACTION; HEMODIALYSIS; HUMAN; HYPOALBUMINEMIA; IMMUNOSUPPRESSIVE TREATMENT; INDUCED HYPOTHERMIA; INTENSIVE CARE; INTERSTITIAL FLUID; INTESTINE ABSORPTION; INTRACRANIAL HYPERTENSION; LIVER BLOOD FLOW; LUNG EDEMA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PERIPHERAL CIRCULATION; PLASMA PROTEIN BINDING; PLEURA EFFUSION; POSITIVE END EXPIRATORY PRESSURE; POSTOPERATIVE ILEUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEPTIC SHOCK; SHOCK; STOMACH EMPTYING; STOMACH MOTILITY; STOMACH PH; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; VASCULAR SURGERY;

ABSORPTION; ADULT; BIOLOGICAL AVAILABILITY; BLOOD-BRAIN BARRIER; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GASTROINTESTINAL TRACT; HEALTHY VOLUNTEERS; HUMANS; HYDROGEN-ION CONCENTRATION; INTENSIVE CARE UNITS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; WOUNDS AND INJURIES;

EID: 84882307273     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.799137     Document Type: Review

References (146)

1. McKindley DS, Hanes S, Boucher BA. Hepatic drug metabolism in critical illness. Pharmacotherapy 1998;18(4):759-78
2. Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22(2):255-71; vi
3. Smith BS, Yogaratnam D, Levasseur-Franklin KE, et al. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012;141(5):1327-36
4. Rowland M, Tozer TN. Clinical pharmacokinetics: concepts and applications. 3rd edition. Lippincott Williams & Wilkins; USA, PA: 1995
5. Barquist ES, Gomez-Fein E, Block EF, et al. Bioavailability of oral fluconazole in critically ill abdominal trauma patients with and without abdominal wall closure: a randomized crossover clinical trial. J Trauma 2007;63(1):159-63
6. Lahner E, Annibale B, Delle Fave G. Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy. Aliment Pharmacol Ther 2009;29(12):1219-29
7. Gupta E, Bansal D, Sotos J, Olden K. Risk of adverse clinical outcomes with concomitant use of clopidogrel and proton pump inhibitors following percutaneous coronary intervention. Dig Dis Sci 2010;55(7):1964-8
8. Heyland DK, Tougas G, King D, Cook DJ. Impaired gastric emptying in mechanically ventilated, critically ill patients. Intensive Care Med 1996;22(12):1339-44
9. Tarling MM, Toner CC, Withington PS, et al. A model of gastric emptying using paracetamol absorption in intensive care patients. Intensive Care Med 1997;23(3):256-60
10. MacLaren R, Patrick WD, Hall RI, et al. Comparison of cisapride and metoclopramide for facilitating gastric emptying and improving tolerance to intragastric enteral nutrition in critically III, mechanically ventilated adults. Clin Ther 2001;23(11):1855-66
11. Papadopoulos J, Smithburger PL. Common drug interactions leading to adverse drug events in the intensive care unit: management and pharmacokinetic considerations. Crit Care Med 2010;38(6 Suppl):S126-35
12. Abernethy DR, Flockhart DA. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation 2000;101(14):1749-53
13. Fricker G, Drewe J, Huwyler J, et al. Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation. Br J Pharmacol 1996;118(7):1841-7
14. Rommers MK, Van der Lely N, Egberts TC, van den Bemt PM. Anti-Xa activity after subcutaneous administration of dalteparin in ICU patients with and without subcutaneous oedema: a pilot study. Crit Care 2006;10(3):R93
15. Jochberger S, Mayr V, Luckner G, et al. Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. Crit Care 2005;9(5):R541-8
16. Cook D, Crowther M, Meade M, et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med 2005;33(7):1565-71
17. Johnston JD, Harvey CJ, Menzies IS, Treacher DF. Gastrointestinal permeability and absorptive capacity in sepsis. Crit Care Med 1996;24(7):1144-9
18. Ziegler TR, Smith RJ, O'Dwyer ST, et al. Increased intestinal permeability associated with infection in burn patients. Arch Surg 1988;123(11):1313-19
19. LeVoyer T, Cioffi WG Jr, Pratt L, et al. Alterations in intestinal permeability after thermal injury. Arch Surg 1992;127(1):26-9; discussion 29-30
20. Roberts DJ, Zygun DA, Grendar J, et al. Negative-pressure wound therapy for critically ill adults with open abdominal wounds: a systematic review. J Trauma Acute Care Surg 2012;73(3):629-39
21. Devlin JW, Welage LS, Olsen KM. Proton pump inhibitor formulary considerations in the acutely ill. Part 1: pharmacology, pharmacodynamics, and available formulations. Ann Pharmacother 2005;39(10):1667-77
22. Nguyen NQ, Ng MP, Chapman M, et al. The impact of admission diagnosis on gastric emptying in critically ill patients. Crit Care 2007;11(1):R16
23. Nguyen NQ, Chapman MJ, Fraser RJ, et al. The effects of sedation on gastric emptying and intra-gastric meal distribution in critical illness. Intensive Care Med 2008;34(3):454-60
24. McArthur CJ, Gin T, McLaren IM, et al. Gastric emptying following brain injury: effects of choice of sedation and intracranial pressure. Intensive Care Med 1995;21(7):573-6
25. Roberts DJ, Banh HL, Hall RI. Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients. Curr Opin Crit Care 2006;12(4):295-302
26. Maka DA, Murphy LK. Drug-nutrient interactions: a review. AACN Clin Issues 2000;11(4):580-9
27. Cohn SM, Sawyer MD, Burns GA, et al. Enteric absorption of ciprofloxacin during tube feeding in the critically ill. J Antimicrob Chemother 1996;38(5):871-6
28. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med 1998;24(10):1047-51
29. de Marie S, VandenBergh MF, Buijk SL, et al. Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. Intensive Care Med 1998;24(4):343-6
30. Kanji S, McKinnon PS, Barletta JF, et al. Bioavailability of gatifloxacin by gastric tube administration with and without concomitant enteral feeding in critically ill patients. Crit Care Med 2003;31(5):1347-52
31. Au Yeung SC, Ensom MH. Phenytoin and enteral feedings: does evidence support an interaction? Ann Pharmacother 2000;34(7-8):896-905
32. Frost RW, Lasseter KC, Noe AJ, et al. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob Agents Chemother 1992;36(4):830-2
33. Zhou SF. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica 2008;38(7-8):802-32
34. Spriet I, Meersseman W, de Hoon J, et al. Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU. Intensive Care Med 2009;35(4):603-12
35. Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002;300(3):1036-45
36. Fernandez C, Buyse M, German-Fattal M, Gimenez F. Influence of the pro-inflammatory cytokines on P-glycoprotein expression and functionality. J Pharm Pharm Sci 2004;7(3):359-71
37. Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clin Pharmacol Ther 2003;74(6):543-54
38. Lemahieu W, Maes B, Verbeke K, et al. Cytochrome P450 3A4 and P-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea. Am J Transplant 2005;5(6):1383-91
39. Dorffler-Melly J, de Jonge E, Pont AC, et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 2002;359(9309):849-50
40. Haas CE, Nelson JL, Raghavendran K, et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma 2005;59(6):1336-44
41. Priglinger U, Delle Karth G, Geppert A, et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med 2003;31(5):1405-9
42. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009;37(3):840-51; quiz 859
43. Holley FO, Ponganis KV, Stanski DR. Effects of cardiac surgery with cardiopulmonary bypass on lidocaine disposition. Clin Pharmacol Ther 1984;35(5):617-26
44. Joukhadar C, Frossard M, Mayer BX, et al. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit Care Med 2001;29(2):385-91
45. Roberts DJ, Goralski KB, Renton KW, et al. Effect of acute inflammatory brain injury on accumulation of morphine and morphine 3-and 6-glucuronide in the human brain. Crit Care Med 2009;37(10):2767-74
46. Goncalves-Pereira J, Povoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of beta-lactams. Crit Care 2011;15(5):R206
47. Gonzalez D, Conrado DJ, Theuretzbacher U, Derendorf H. The effect of critical illness on drug distribution. Curr Pharm Biotechnol 2011;12(12):2030-6
48. Niemiec PW Jr, Allo MD, Miller CF. Effect of altered volume of distribution on aminoglycoside levels in patients in surgical intensive care. Arch Surg 1987;122(2):207-12
49. Dasta JF, Armstrong DK. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit Care Med 1988;16(4):327-30
50. Townsend PL, Fink MP, Stein KL, Murphy SG. Aminoglycoside pharmacokinetics: dosage requirements and nephrotoxicity in trauma patients. Crit Care Med 1989;17(2):154-
51. Conil JM, Georges B, Breden A, et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 2006;28(3):226-30
52. Taccone FS, de Backer D, Laterre PF, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011;37(6):531-5
53. Rafati MR, Rouini MR, Mojtahedzadeh M, et al. Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients. Int J Antimicrob Agents 2006;28(2):122-7
54. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T > MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008;31(4):345-51
55. Sakka SG, Glauner AK, Bulitta JB, et al. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob Agents Chemother 2007;51(9):3304-10
56. Thalhammer F, Traunmuller F, El Menyawi I, et al. Continuous infusion versus intermittent administration of meropenem in critically ill patients. J Antimicrob Chemother 1999;43(4):523-7
57. Martyn J. Clinical pharmacology and drug therapy in the burned patient. Anesthesiology 1986;65(1):67-75
58. Benet LZ, Hoener BA. Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Ther 2002;71(3):115-21
59. Fleck A, Raines G, Hawker F, et al. Increased vascular permeability: a major cause of hypoalbuminaemia in disease and injury. Lancet 1985;1(8432):781-4
60. Boucher BA, Rodman JH, Jaresko GS, et al. Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1988;44(6):675-83
61. Malacrida R, Fritz ME, Suter PM, Crevoisier C. Pharmacokinetics of midazolam administered by continuous intravenous infusion to intensive care patients. Crit Care Med 1992;20(8):1123-6
62. Martyn JA, Abernethy DR, Greenblatt DJ. Plasma protein binding of drugs after severe burn injury. Clin Pharmacol Ther 1984;35(4):535-9
63. Joukhadar C, Klein N, Mayer BX, et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Crit Care Med 2002;30(7):1478-82
64. Brunner M, Pernerstorfer T, Mayer BX, et al. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 2000;28(6):1754-9
65. Roberts DJ, Goralski KB. A critical overview of the influence of inflammation and infection on P-glycoprotein expression and activity in the brain. Expert Opin Drug Metab Toxicol 2008;4(10):1245-64
66. Boucher BA, Hanes SD. Pharmacokinetic alterations after severe head injury. Clinical relevance. Clin Pharmacokinet 1998;35(3):209-21
67. Goralski KB, Hartmann G, Piquette-Miller M, Renton KW. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 2003;139(1):35-48
68. Meineke I, Freudenthaler S, Hofmann U, et al. Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine. Br J Clin Pharmacol 2002;54(6):592-603
69. Shedlofsky SI, Israel BC, McClain CJ, et al. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J Clin Invest 1994;94(6):2209-14
70. Shedlofsky SI, Israel BC, Tosheva R, Blouin RA. Endotoxin depresses hepatic cytochrome P450-mediated drug metabolism in women. Br J Clin Pharmacol 1997;43(6):627-32
71. Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008;36(2):205-16
72. Haas CE, Kaufman DC, Jones CE, et al. Cytochrome P450 3A4 activity after surgical stress. Crit Care Med 2003;31(5):1338-46
73. Henrion J, Schapira M, Luwaert R, et al. Hypoxic hepatitis: clinical and hemodynamic study in 142 consecutive cases. Medicine (Baltimore) 2003;82(6):392-406
74. Hiraoka H, Yamamoto K, Okano N, et al. Changes in drug plasma concentrations of an extensively bound and highly extracted drug, propofol, in response to altered plasma binding. Clin Pharmacol Ther 2004;75(4):324-30
75. van den Broek MP, Groenendaal F, Egberts AC, Rademaker CM. Effects of hypothermia on pharmacokinetics and pharmacodynamics: a systematic review of preclinical and clinical studies. Clin Pharmacokinet 2010;49(5):277-94
76. Memis D, Kargi M, Sut N. Effects of propofol and dexmedetomidine on indocyanine green elimination assessed with LIMON to patients with early septic shock: a pilot study. J Crit Care 2009;24(4):603-8
77. Nygren A, Thoren A, Ricksten SE. Vasopressin decreases intestinal mucosal perfusion: a clinical study on cardiac surgery patients in vasodilatory shock. Acta Anaesthesiol Scand 2009;53(5):581-8
78. DeBacker D, Creteur J, Silva E, Vincent JL. Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is best? Crit Care Med 2003;31(6):1659-67
79. Guerin JP, Levraut J, Samat-Long C, et al. Effects of dopamine and norepinephrine on systemic and hepatosplanchnic hemodynamics, oxygen exchange, and energy balance in vasoplegic septic patients. Shock 2005;23(1):18-24
80. Sun H, Frassetto L, Benet LZ. Effects of renal failure on drug transport and metabolism. Pharmacol Ther 2006;109(1-2):1-11
81. Park GR. Molecular mechanisms of drug metabolism in the critically ill. Br J Anaesth 1996;77(1):32-49
82. Harbrecht BG, Frye RF, Zenati MS, et al. Cytochrome P-450 activity is differentially altered in severely injured patients. Crit Care Med 2005;33(3):541-6
83. Skrobik Y, Leger C, Cossette M, et al. Factors predisposing to coma and delirium: fentanyl and midazolam exposure; CYP3A5, ABCB1, and ABCG2 genetic polymorphisms; and inflammatory factors. Crit Care Med 2013;41(4):999-1008
84. Renton KW. Regulation of drug metabolism and disposition during inflammation and infection. Expert Opin Drug Metab Toxicol 2005;1(4):629-40
85. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010;49(1):1-16
86. Desjars P, Pinaud M, Bugnon D, Tasseau F. Norepinephrine therapy has no deleterious renal effects in human septic shock. Crit Care Med 1989;17(5):426-9
87. Marin C, Eon B, Saux P, et al. Renal effects of norepinephrine used to treat septic shock patients. Crit Care Med 1990;18(3):282-5
88. Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. Intensive Care Med 1993;19(3):151-4
89. Baptista JP, Udy AA, Sousa E, et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011;15(3):R139
90. Larijani GE, Gratz I, Silverberg M, Jacobi AG. Clinical pharmacology of the neuromuscular blocking agents. DICP 1991;25(1):54-64
91. Power BM, Forbes AM, van Heerden PV, Ilett KF. Pharmacokinetics of drugs used in critically ill adults. Clin Pharmacokinet 1998;34(1):25-56
92. Ward S, Weatherley BC. Pharmacokinetics of atracurium and its metabolites. Br J Anaesth 1986;58(Suppl 1):6S-10S
93. Booij LH, Vree TB. Skeletal muscle relaxants: pharmacodynamics and pharmacokinetics in different patient groups. Int J Clin Pract 2000;54(8):526-34
94. Somogyi AA, Shanks CA, Triggs EJ. Disposition kinetics of pancuronium bromide in patients with total biliary obstruction. Br J Anaesth 1977;49(11):1103-8
95. Vandenbrom RH, Wierda JM. Pancuronium bromide in the intensive care unit: a case of overdose. Anesthesiology 1988;69(6):996-7
96. Lebrault C, Berger JL, D'Hollander AA, et al. Pharmacokinetics and pharmacodynamics of vecuronium (ORG NC 45) in patients with cirrhosis. Anesthesiology 1985;62(5):601-5
97. Lebrault C, Duvaldestin P, Henzel D, et al. Pharmacokinetics and pharmacodynamics of vecuronium in patients with cholestasis. Br J Anaesth 1986;58(9):983-7
98. Segredo V, Caldwell JE, Matthay MA, et al. Persistent paralysis in critically ill patients after long-term administration of vecuronium. N Engl J Med 1992;327(8):524-8
99. Sparr HJ, Wierda JM, Proost JH, et al. Pharmacodynamics and pharmacokinetics of rocuronium in intensive care patients. Br J Anaesth 1997;78(3):267-73
100. Moore EW, Hunter JM. The new neuromuscular blocking agents: do they offer any advantages? Br J Anaesth 2001;87(6):912-25
101. Reeves ST, Turcasso NM. Nondepolarizing neuromuscular blocking drugs in the intensive care unit: a clinical review. South Med J 1997;90(8):769-74
102. Khuenl-Brady KS, Sparr H. Clinical pharmacokinetics of rocuronium bromide. Clin Pharmacokinet 1996;31(3):174-83
103. Sparr HJ, Beaufort TM, Fuchs-Buder T. Newer neuromuscular blocking agents: how do they compare with established agents? Drugs 2001;61(7):919-42
104. Khalil M, D'Honneur G, Duvaldestin P, et al. Pharmacokinetics and pharmacodynamics of rocuronium in patients with cirrhosis. Anesthesiology 1994;80(6):1241-7
105. van Miert MM, Eastwood NB, Boyd AH, et al. The pharmacokinetics and pharmacodynamics of rocuronium in patients with hepatic cirrhosis. Br J Clin Pharmacol 1997;44(2):139-44
106. Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth 2000;85(5):717-23
107. Hull CJ. Pharmacokinetics and pharmacodynamics of the benzylisoquinolinium muscle relaxants. Acta Anaesthesiol Scand Suppl 1995;106:13-17
108. Fahey MR, Rupp SM, Fisher DM, et al. The pharmacokinetics and pharmacodynamics of atracurium in patients with and without renal failure. Anesthesiology 1984;61(6):699-702
109. Stiller RL, Brandom BW, Cook DR. Determination of atracurium in plasma by high-performance liquid chromatography. Anesth Analg 1985;64(1):58-62
110. Welch RM, Brown A, Ravitch J, Dahl R. The in vitro degradation of cisatracurium, the R, cis-R'-isomer of atracurium, in human and rat plasma. Clin Pharmacol Ther 1995;58(2):132-42
111. De Wolf AM, Freeman JA, Scott VL, et al. Pharmacokinetics and pharmacodynamics of cisatracurium in patients with end-stage liver disease undergoing liver transplantation. Br J Anaesth 1996;76(5):624-8
112. Kisor DF, Schmith VD. Clinical pharmacokinetics of cisatracurium besilate. Clin Pharmacokinet 1999;36(1):27-40
113. Kisor DF, Schmith VD, Wargin WA, et al. Importance of the organ-independent elimination of cisatracurium. Anesth Analg 1996;83(5):1065-71
114. Cook DR, Freeman JA, Lai AA, et al. Pharmacokinetics of mivacurium in normal patients and in those with hepatic or renal failure. Br J Anaesth 1992;69(6):580-5
115. Devlin JC, Head-Rapson AG, Parker CJ, Hunter JM. Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. Br J Anaesth 1993;71(2):227-31
116. Head-Rapson AG, Devlin JC, Parker CJ, Hunter JM. Pharmacokinetics of the three isomers of mivacurium and pharmacodynamics of the chiral mixture in hepatic cirrhosis. Br J Anaesth 1994;73(5):613-18
117. Head-Rapson AG, Devlin JC, Parker CJ, Hunter JM. Pharmacokinetics and pharmacodynamics of the three isomers of mivacurium in health, in end-stage renal failure and in patients with impaired renal function. Br J Anaesth 1995;75(1):31-6
118. Atherton DP, Hunter JM. Clinical pharmacokinetics of the newer neuromuscular blocking drugs. Clin Pharmacokinet 1999;36(3):169-89
119. Murray MJ, Cowen J, DeBlock H, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002;30(1):142-56
120. Hall R. The pharmacokinetic behaviour of opioids administered during cardiac surgery. Can J Anaesth 1991;38(6):747-56
121. Hall RI. Changes in the pharmacokinetics and pharmacodynamics of drugs administered during cardiopulmonary bypass. In: Gravlee GP, Davis RF, Kurusz M, Utley JR, editors. Cardiopulmonary bypass-principles and practice. 2nd edition. Lippincott Williams & Wilkins; Baltimore, MD: 2000. p. 265-303
122. Hall RI. Cardiopulmonary bypass and the systemic inflammatory response: effects on drug action. J Cardiothorac Vasc Anesth 2002;16(1):83-98
123. Yamaura K, Okamoto H, Akiyoshi K, et al. Effect of low-dose milrinone on gastric intramucosal pH and systemic inflammation after hypothermic cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2001;15(2):197-203
124. Thoren A, Elam M, Ricksten SE. Jejunal mucosal perfusion is well maintained during mild hypothermic cardiopulmonary bypass in humans. Anesth Analg 2001;92(1):5-11
125. Petros A, Dunne N, Mehta R, et al. The pharmacokinetics of alfentanil after normothermic and hypothermic cardiopulmonary bypass. Anesth Analg 1995;81(3):458-64
126. Bisschops LL, Hoedemaekers CW, Mollnes TE, van der Hoeven JG. Rewarming after hypothermia after cardiac arrest shifts the inflammatory balance. Crit Care Med 2012;40(4):1136-42
127. Heradstveit BE, Guttormsen AB, Langorgen J, et al. Capillary leakage in post-cardiac arrest survivors during therapeutic hypothermia-A prospective, randomised study. Scand J Trauma Resusc Emerg Med 2010;18:29
128. Aslami H, Binnekade JM, Horn J, et al. The effect of induced hypothermia on respiratory parameters in mechanically ventilated patients. Resuscitation 2010;81(12):1723-5
129. Fukuoka N, Aibiki M, Tsukamoto T, et al. Biphasic concentration change during continuous midazolam administration in brain-injured patients undergoing therapeutic moderate hypothermia. Resuscitation 2004;60(2):225-30
130. Bjelland TW, Klepstad P, Haugen BO, et al. Effects of hypothermia on the disposition of morphine, midazolam, fentanyl, and propofol in intensive care unit patients. Drug Metab Dispos 2013;41(1):214-23
131. Zhou J, Poloyac SM. The effect of therapeutic hypothermia on drug metabolism and response: cellular mechanisms to organ function. Expert Opin Drug Metab Toxicol 2011;7(7):803-16
132. Leslie K, Sessler DI, Bjorksten AR, Moayeri A. Mild hypothermia alters propofol pharmacokinetics and increases the duration of action of atracurium. Anesth Analg 1995;80(5):1007-14
133. Hostler D, Zhou J, Tortorici MA, et al. Mild hypothermia alters midazolam pharmacokinetics in normal healthy volunteers. Drug Metab Dispos 2010;38(5):781-8
134. Caldwell JE, Heier T, Wright PM, et al. Temperature-dependent pharmacokinetics and pharmacodynamics of vecuronium. Anesthesiology 2000;92(1):84-93
135. Russell D, Royston D, Rees PH, et al. Effect of temperature and cardiopulmonary bypass on the pharmacokinetics of remifentanil. Br J Anaesth 1997;79(4):456-9
136. Mercer JM, Neyens RR. Aminoglycoside pharmacokinetic parameters in neurocritical care patients undergoing induced hypothermia. Pharmacotherapy 2010;30(7):654-60
137. Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother 2006;40(1):9-14
138. Trotman RL, Williamson JC, Shoemaker DM, Salzer WL. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis 2005;41(8):1159-66
139. Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med 2009;37(7):2268-82
140. Teigen MM, Duffull S, Dang L, Johnson DW. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol 2006;46(11):1259-67
141. Mehrotra R, De Gaudio R, Palazzo M. Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 2004;30(12):2145-56
142. Mulla H, Pooboni S. Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 2005;60(3):265-75
143. Pea F, Viale P, Pavan F, Furlanut M. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet 2007;46(12):997-1038
144. DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004;58(3):259-68
145. Isla A, Rodriguez-Gascon A, Troconiz IF, et al. Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy. Clin Pharmacokinet 2008;47(3):173-80
146. Roberts DJ, Haroon B, Hall RI. Sedation for critically ill or injured adults in the intensive care unit: a shifting paradigm. Drugs 2012;72(14):1881-916